Cassava Sciences (SAVA) Expected to Announce Quarterly Earnings on Tuesday

Cassava Sciences (NASDAQ:SAVA) is expected to post its Q4 2025 results before the market opens on Tuesday, March 3rd. Analysts expect Cassava Sciences to post earnings of ($0.30) per share for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, March 10, 2026 at 10:30 AM ET.

Cassava Sciences Stock Down 3.0%

NASDAQ SAVA opened at $2.28 on Monday. Cassava Sciences has a 52 week low of $1.15 and a 52 week high of $4.98. The stock has a market capitalization of $110.15 million, a PE ratio of -1.04 and a beta of -0.85. The firm has a 50 day moving average of $2.12 and a two-hundred day moving average of $2.68.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on SAVA. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cassava Sciences in a research report on Friday, December 26th. Wall Street Zen cut Cassava Sciences from a “hold” rating to a “sell” rating in a research note on Saturday. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Reduce” and an average target price of $2.00.

Hedge Funds Weigh In On Cassava Sciences

Several large investors have recently bought and sold shares of the stock. Jump Financial LLC acquired a new stake in shares of Cassava Sciences in the 4th quarter valued at about $181,000. Federated Hermes Inc. increased its position in Cassava Sciences by 111.3% during the fourth quarter. Federated Hermes Inc. now owns 91,479 shares of the company’s stock worth $181,000 after buying an additional 48,194 shares during the period. Strs Ohio purchased a new stake in Cassava Sciences in the first quarter valued at approximately $178,000. OMERS ADMINISTRATION Corp purchased a new stake in Cassava Sciences in the fourth quarter valued at approximately $166,000. Finally, Marshall Wace LLP acquired a new stake in shares of Cassava Sciences in the second quarter valued at approximately $130,000. Institutional investors and hedge funds own 38.05% of the company’s stock.

About Cassava Sciences

Cassava Sciences, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies and diagnostics for Alzheimer’s disease and related neurodegenerative disorders. Headquartered in Austin, Texas, the company was originally founded as Pain Therapeutics in 1998 and rebranded to Cassava Sciences in 2017. Cassava’s research program centers on small molecules designed to address underlying mechanisms of neurodegeneration rather than solely targeting amyloid plaques or tau tangles.

The company’s lead drug candidate, simufilam (formerly PTI-125), is a proprietary small molecule that aims to restore normal shape and function to the scaffolding protein filamin A, which has been implicated in impaired neuronal signaling and inflammation in Alzheimer’s patients.